Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 25 of 70 entries
View as:

Octagam 5% Versus Comparator Post Marketing Trial

Phase: N/A Priority: Normal
NCT ID: NCT01859754 Org: User:
Start: 05/21/13 End: 05/22/19 Due: 05/22/20

Observational Study of the Use of octaplasLG®.

Phase: N/A Priority: Normal
NCT ID: NCT03369314 Org: User:
Start: 03/02/18 End: 01/14/21 Due: 01/14/22

Efficacy and Safety Study of Human-cl rhFVIII in PTPs With Severe Hemophilia A

Phase: N/A Priority: Normal
NCT ID: NCT01125813 Org: User:
Start: 06/30/10 End: 01/31/12 Due: 01/31/13

Human Cell Line-derived Recombinant Factor VIII (Human-cl-rhFVIII) in Previously Untreated Patients

Phase: N/A Priority: Normal
NCT ID: NCT01712438 Org: User:
Start: 02/28/13 End: 12/20/19 Due: 12/20/20

Assess the Safety and Efficacy of Individually Tailored Prophylaxis With Human-cl rhFVIII in Patients With Severe Haemophilia A

Phase: N/A Priority: Normal
NCT ID: NCT01863758 Org: User:
Start: 08/31/13 End: 01/31/15 Due: 01/31/16

Study of Octanorm Subcutaneous IG in Patients With PID

Phase: N/A Priority: Normal
NCT ID: NCT01888484 Org: User:
Start: 03/31/14 End: 06/09/20 Due: 06/09/21

Post Marketing Observational Study on Safety of BALFAXAR vs. KCENTRA for Reversal of Vitamin K Antagonist Induced Anticoagulation in Adults Undergoing Urgent Surgery or Invasive Procedure

Phase: N/A Priority: Normal
NCT ID: NCT06429787 Org: User:
Start: 02/14/25 End: 06/30/32 Due: 06/30/33

Bleeding Incidence in VWD Patients Undergoing On-Demand Treatment

Phase: N/A Priority: Normal
NCT ID: NCT04053699 Org: User:
Start: 06/25/19 End: 01/31/21 Due: 01/31/22

A Study of NewGam, Human Immunoglobulin 10%, in Patients With Primary Immunodeficiency Diseases

Phase: N/A Priority: Normal
NCT ID: NCT01012323 Org: User:
Start: 01/31/10 End: 06/30/12 Due: 06/30/13

The Effect of Subcutaneous Immunoglobulin Gammanorm on the Distribution of IgG Subclasses and on Immunity of Patients With Secondary Immunodeficiency

Phase: N/A Priority: Normal
NCT ID: NCT03369301 Org: User:
Start: 09/25/17 End: 11/22/19 Due: 11/22/20

A Trial to Investigate the Relative Efficacy, Safety, and Tolerability of Octaplas LG Versus Octaplas SD

Phase: N/A Priority: Normal
NCT ID: NCT01063595 Org: User:
Start: 12/31/09 End: 07/31/10 Due: 07/31/11

Wilate in Subjects With Von Willebrand Disease Who Undergo Surgery

Phase: N/A Priority: Normal
NCT ID: NCT01365546 Org: User:
Start: 06/30/11 End: 04/30/14 Due: 04/30/15

Evaluation of the Safety of Octaplas™ Versus Plasma in Patients Undergoing Orthotopic Liver Transplantation

Phase: N/A Priority: Normal
NCT ID: NCT02037373 Org: User:
Start: 08/31/15 End: 02/28/18 Due: 02/28/19

Study of Octagam (Intravenous Immunoglobulin [IVIG]) 10% on the Treatment of Mild to Moderate Alzheimer's Disease

Phase: N/A Priority: Normal
NCT ID: NCT00812565 Org: User:
Start: 02/28/09 End: 09/30/10 Due: 09/30/11

Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Wilate in Previously Treated Paediatric Patients With Severe Haemophilia A

Phase: N/A Priority: Normal
NCT ID: NCT03376516 Org: User:
Start: 11/22/17 End: 11/03/18 Due: 11/03/19

Immune Tolerance Induction in Haemophilia A Patients Using Wilate or Nuwiq

Phase: N/A Priority: Normal
NCT ID: NCT03344003 Org: User:
Start: 06/28/18 End: 11/20/20 Due: 11/20/21

Study Evaluating Efficacy and Safety of Octanorm in Patients With Dermatomyositis

Phase: N/A Priority: Normal
NCT ID: NCT03686969 Org: User:
Start: 08/02/18 End: 11/29/18 Due: 11/29/19

Efficacy and Safety Study of Octafibrin for On-demand Treatment of Acute Bleeding and to Prevent Bleeding During and After Surgery

Phase: N/A Priority: Normal
NCT ID: NCT02267226 Org: User:
Start: 09/30/14 End: 02/14/18 Due: 02/14/19

Nuwiq for Perioperative Management Of Patients With Haemophilia A on Emicizumab Regular Prophylaxis Study

Phase: N/A Priority: Normal
NCT ID: NCT05935358 Org: User:
Start: 11/28/23 End: 08/31/26 Due: 08/31/27

Efficacy, Safety & Utilisation of Nuwiq, Octanate and Wilate in Previously Untreated & Minimally Treated Haemophilia A Patients

Phase: N/A Priority: Normal
NCT ID: NCT03695978 Org: User:
Start: 02/13/18 End: 06/30/30 Due: 06/30/31

High Infusion Rate Study of Immunoglobulin Intravenous (Human) 10% (NewGam)

Phase: N/A Priority: Normal
NCT ID: NCT01313507 Org: User:
Start: 05/31/11 End: 09/30/12 Due: 09/30/13

Study to Evaluate Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Patients

Phase: N/A Priority: Normal
NCT ID: NCT04929236 Org: User:
Start: 10/01/23 End: 06/30/26 Due: 06/30/27

Safety and Efficacy Study of Three Different Dosages of NewGam in Patients With CIDP

Phase: N/A Priority: Normal
NCT ID: NCT01225276 Org: User:
Start: 10/31/11 End: 10/31/12 Due: 10/31/13

Study to Assess the Efficacy, Safety and Pharmacokinetic of Octafibrin in Paediatric Subjects With Fibrinogen Deficiency

Phase: N/A Priority: Normal
NCT ID: NCT02408484 Org: User:
Start: 12/31/15 End: 06/11/19 Due: 06/11/20

Nuwiq Dosing and Outcomes In the ManagEment of Women/Girls With Haemophilia A Needing FVIII Treatment for Surgery

Phase: N/A Priority: Normal
NCT ID: NCT05936580 Org: User:
Start: 09/30/25 End: 02/28/27 Due: 02/28/28